Sub menu

Australian prescription medicine decision summaries

Search our decision summaries for the registration of new prescription medicines.

For more information, visit the About Australian prescription medicine decision summaries information page.

We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia. 

The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Published date

262 result(s) found, displaying 101 to 125

  • Radicava

    Prescription medicine decision summary
    TGA decision: Radicava (edaravone) is approved to treat adults with a diagnosis of amyotrophic lateral sclerosis.

  • Nuceiva

    Prescription medicine decision summary
    Nuceiva (prabotulinumtoxinA) is approved to treat glabellar lines.

  • Doptelet

    Prescription medicine decision summary
    Doptelet (avatrombopag maleate) is approved to treat thrombocytopenia in adult patients.

  • Mounjaro

    Prescription medicine decision summary
    Mounjaro (tirzepatide) is approved to treat diabetes.

  • Welireg

    Prescription medicine decision summary
    Welireg (belzutifan) is approved to treat adult patients with von Hippel-Lindau (VHL) disease

  • Evusheld

    Prescription medicine decision summary
    Evusheld (tixagevimab and cilgavimab) is approved to treat COVID-19

  • Prevenar 20

    Prescription medicine decision summary
    TGA decision: Prevenar 20 (Pneumococcal purified capsular polysaccharides) is approved to prevent pneumococcal disease.

  • Rybrevant

    Prescription medicine decision summary
    TGA decision: Rybrevant (amivantamab) is approved to treat lung cancer

  • Sotyktu

    Prescription medicine decision summary
    Sotyktu (deucravacitinib) is approved to treat plaque psoriasis.

  • Letybo

    Prescription medicine decision summary
    TGA decision: Letybo (letibotulinumtoxinA) is approved to treat the appearance of moderate to severe glabellar frown lines in adults.

  • Onpattro

    Prescription medicine decision summary
    Onpattro (patisiran) is approved to treat polyneuropathy.

  • Korsuva

    Prescription medicine decision summary
    Korsuva (difelikefalin acetate) is approved to treat chronic kidney disease

  • Vazkepa

    Prescription medicine decision summary
    Vazkepa (Icosapent ethyl) is approved to treat cardiovascular disease.

  • Vabysmo

    Prescription medicine decision summary
    Vabysmo (faricimab) is approved to treat macular degeneration.

  • Verorab

    Prescription medicine decision summary
    Verorab (inactivated rabies virus) is approved to treat rabies.

  • Livtencity

    Prescription medicine decision summary
    Livtencity (maribavir) is approved to treat cytomegalovirus (CMV).

  • Camzyos

    Prescription medicine decision summary
    Camzyos (mavacamten) is approved to treat cardiomyopathy.

  • Trecondi

    Prescription medicine decision summary
    Trecondi (treosulfan) is approved to treat cancer

  • Ciptunec/Ardalicip

    Prescription medicine decision summary
    TGA decision: Ciptunec Ardalicip (adalimumab) is approved to treat arthritis.

  • Pemazyre

    Prescription medicine decision summary
    TGA decision: Pemazyre (pemigatinib) is approved to treat cancer

  • Byooviz

    Prescription medicine decision summary
    TGA decision: Byooviz (ranibizumab) is approved to treat visual impairment.

  • Filpegla

    Prescription medicine decision summary
    TGA decision: Filpegla (pegfilgrastim) is approved for the treatment of cancer patients following chemotherapy.